First demonstration of the effectiveness of peptide receptor radionuclide therapy (PRRT) with 111In-DTPA-octreotide in a giant PRL-secreting pituitary adenoma resistant to conventional treatment

Pituitary

Volumn 15, Issue 1 SUPPL., 2012, Pages

  Baldari, S ^a   Ferrau F ^a   Alafaci, C ^a   Herberg, A ^a   Granata, F ^a   Militano, V ^a   Salpietro, F M ^a   Trimarchi, F ^a   Cannavo S ^a  

^a UNIVERSITY OF MESSINA   (Italy)

Author keywords

111Indium DTPA octreotide; Cabergoline resistance; Giant prolactinoma; Peptide receptor radionuclide therapy; PRL secreting pituitary adenoma

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; OCTREOTIDE; PENTETATE INDIUM IN 111; PROLACTIN; TEMOZOLOMIDE; DRUG DERIVATIVE; INDIUM 111 OCTREOTIDE; INDIUM-111-OCTREOTIDE;

ADULT; ARTICLE; BRAIN INJURY; BRAIN SCINTISCANNING; BRAIN THIRD VENTRICLE; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CASE REPORT; CAVERNOUS SINUS; CLINICAL EFFECTIVENESS; COGNITIVE DEFECT; CYTOREDUCTIVE SURGERY; DISEASE ACTIVITY; DISEASE COURSE; DISORIENTATION; DRUG TOLERANCE; EYE MOVEMENT; FEMALE; GLASGOW COMA SCALE; HIPPOCAMPUS; HUMAN; MESENCEPHALON; MULTIPLE CYCLE TREATMENT; MYDRIASIS; NEUROIMAGING; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSTRUCTIVE HYDROCEPHALUS; OPHTHALMOPLEGIA; PEPTIDE RECEPTOR RADIONUCLEOTIDE THERAPY; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTINOMA; PTOSIS; RADIOISOTOPE THERAPY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TRANSSPHENOIDAL SURGERY; TREATMENT CONTRAINDICATION; TREATMENT FAILURE; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VOLUME; MIDDLE AGED; SCINTISCANNING;

FEMALE; HUMANS; MIDDLE AGED; OCTREOTIDE; PROLACTINOMA;

EID: 84877147156     PISSN: 1386341X     EISSN: 15737403     Source Type: Journal    
DOI: 10.1007/s11102-011-0373-5     Document Type: Article

References (30)

1. Colao A, Di Sarno A, Pivonello R, Di Somma C, Lombardi G (2002) Dopamine receptor agonists for treating prolactinomas. Expert Opin Investig Drugs 11:787-800
2. Colao A (2009) Pituitary tumours: the prolactinoma. Best Pract Res Clin Endocrinol Metab 23:575-596
3. Gillam MP, Molitch ME, Lombardi G, Colao A (2006) Advances in the treatment of prolactinomas. Endocr Rev 27(5):485-534
4. Acosta-Gómez MJ, Muros MA, Llamas-Elvira JM, Ramírez A, Ortega S, Sabatel G, Ramos C, de la Riva-Aguilar A (2005) The role of somatostatin receptor scintigraphy in patients with pituitary adenoma or post-surgical recurrent tumours. Br J Radiol 78(926):110-115
5. Jaquet P, Ouafik L, Saveanu A, Gunz G, Fina F, Dufour H, Culler MD, Moreau JP, Enjalbert A (1999) Quantitative and functional expression of somatostatin receptor subtypes in human prolactinomas. J Clin Endocrinol Metab 84(9):3268-3276
6. Corsello SM, Ubertini G, Altomare M, Lovicu RM, Migneco MG, Rota CA, Colosimo C (2003) Giant Prolactinomas in men: efficacy of cabergoline treatment. Clin Endocrinol 58:662-670
7. Shimon I, Benbassat C, Hadani M (2007) Effectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men. Eur J Endocrinol 156(2):225-231
8. Acharya SV, Gopal RA, Menon PS, Bandgar TR, Shah NS (2010) Giant prolactinoma and effectiveness of medical management. Endocr Pract 16(1):42-46
9. Cannavò S, Bartolone L, Blandino A, Spinella S, Galatioto S, Trimarchi F (1999) Shrinkage of a PRL-secreting pituitary macroadenoma resistant to cabergoline. J Endocrinol Invest 22(4):306-309
10. Byrne S, Karapetis C, Vrodos N (2009) A novel use of temozolomide in a patient with malignant prolactinoma. J Clin Neurosci 16(12):1694-1696
11. Lau Q, Scheithauer B, Kovacs K, Horvath E, Syro LV, Lloyd R (2010) MGMT immunoexpression in aggressive pituitary adenoma and carcinoma. Pituitary 13(4):367-379
12. Greenman Y, Melmed S (1994) Expression of three somatostatin receptor subtypes in pituitary adenomas: evidence for preferential SSTR5 expression in the mammosomatotroph lineage. J Clin Endocrinol Metab 79:724-729
13. Thodou E, Kontogeorgos G, Theodossiou D, Pateraki M (2006) Mapping of somatostatin receptor types in GH or/and PRL producing pituitary adenomas. J Clin Pathol 59:274-279
14. Ur E, Mather SJ, Bomanji J, Ellison D, Britton KE, Grossman AB, Wass JA, Besser JM (1992) Pituitary imaging using a labelled somatostatin analogue in acromegaly. Clin Endocrinol (Oxf) 36(2):147-150
15. Boni G, Ferdeghini M, Bellina CR, Matteucci F, Castro Lopez E, Parenti G, Canapicchi R, Bianchi R (1995) [111In-DTPA-D-Phe]-octreotide scintigraphy in functioning and non-functioning pituitary adenomas. Q J Nucl Med 39:90-93
16. de Herder WW, Kwekkeboom DJ, Reijs AEM (1996) Receptor scintigraphy with somatostatin analogues and dopamine antagonists of pituitary tumours. In: Von Werder K, Fahlbusch R (eds) Pituitary adenomas. From basic research to diagnosis and therapy. Elsevier, Amsterdam, pp 93-104
17. Rieger A, Rainov NG, Elfrich C, Klaua M, Meyer H, Lautenschlager C, Burkert W, Mende T (1997) Somatostatin receptor scintigraphy in patients with pituitary adenoma. Neurosurg Rev 20(1):7-12
18. Kwekkeboom DJ, de Herder WW, Krenning EP (1999) Receptor imaging in the diagnosis and treatment of pituitary tumors. J Endocrinol Invest 22(1):80-88
19. Colao A, Lastoria S, Ferone D, Varrella P, Marzullo P, Pivonello R, Cerbone G, Acampa W, Salvatore M, Lombardi G (1999) The pituitary uptake of (111)In-DTPA-D-Phe1-octreotide in the normal pituitary and in pituitary adenomas. J Endocrinol Invest 22(3):176-183
20. Moulik PK, Varma TRK, Vora JP, Vinjamuri S (2002) The role of somatosatin receptor scintigraphy in the management of pituitary tumours. Nucl Med Commun 23:117-120
21. Plockinger U, Bader M, Hopfenmuller W, Saeger W, Quabbe HJ (1997) Results of somatostatin receptor scintigraphy do not predict pituitary tumor volume- and hormone-response to octreotide therapy and do not correlate with tumor histology. Eur J Endocrinol 136(4):369-376
22. Ferone D, Pivonello R, Lastoria S, Faggiano A, Ferone D, Lombardi G, Fenzi G (2001) In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy. Clin Endocrinol (Oxf) 54(4):469-477
23. Fusco A, Gunz G, Jacquet P, Dufour H, Germanetti AL, Culler MD, Barlier A, Saveanu A (2008) Somatostatinergic ligands in dopamine-sensitive and resistant prolactinomas. Eur J Endocrinol 158:599-603
24. Hofland LJ, Feelders RA, de Herder WW, Lamberts SW (2010) Pituitary tumours: the sst/D2 receptors as molecular targets. Mol Cell Endocrinol 326:89-98
25. Meyer P, Bohnen NI, Barkan AL, Shapiro B (1999) Somatostatinrezeptorszintigraphie bei einem Patienten mit invasivem Makroprolaktinom. Somatostatin receptor scintigraphy of a patient with a giant invasive prolactinoma. Nuklearmedizin 38(2):66-67
26. Fusco A, Lugli F, Sacco E, Tilaro L, Bianchi A, Angelini F, Tofani A, Barini A, Lauriola L, Maira G, Pontecorvi A, de Marinis L (2009) Efficacy of the combined cabergoline and octreotide treatment in a case of a dopamine-agonist resistant macroprolactinoma. Pituitary [Epub ahead of print]
27. de Herder WW, Ferone D, Kwekkeboom D, Lamberts SWJ (2000) Scintigraphy of pituitary tumors. In: de Herder WW (ed) Functional and morphological imaging of the endocrine system, Endocrine Updates Series. Kluwer, Boston, pp 47-58
28. de Herder WW, Lamberts SWJ (2005) Somatostatin analogs as radiodiagnostic tools. Rev Endocr Metab Disord 6:23-27
29. de Herder WW, Kwekkeboom DJ, Feelders RA, van Aken MO, Lamberts SW, van der Lely AJ, Krenning EP (2006) Somatostatin receptor imaging for neuroendocrine tumors. Pituitary 9:243-248
30. Goglia U, Ferone D, Sidoti M, Spaziante R, Dadati P, Ravetti JL, Villa G, Bodei L, Paganelli G, Minuto F, Giusti M (2008) Treatment of a pituitary metastasis from a neuroendocrine tumour: case report and literature review. Pituitary 11(1):93-102